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quent timepoints. By 24 hours, average RO for eptifibatide was 66%, whereas abciximab 
averaged only 67%. Conclusion: These data support the hypothesis that differences in 
clinical outcomes of large GPllb-llla trials in patients with NSTE ACS may be related to 
the consistency and potency of antiplatelet effects. 
1124-90 Platelet Activation as a Predictor of Acute Coronary 
Syndrome in Patients Who Present to the Emergency 
Department With Chest Pain 
Carrie L. Selvarai. Eric Vandegraaff. Brad Abels, John Marshall, Steven R. Steinhubl, 
Wilford Hall Medical Center, Lackland Air Force Base, TX 
Background: Platelet activation and coronary thrombosis are central to the pathophysiol- 
ogy of acute coronary syndromes, which only occasionally manifest with elevated enzy- 
matic markers of myocardial necrosis. The ability to rapidly identify patients with 
increased platelet activation using a simple bedside test may allow for the early identifi- 
cation of those at highest risk for major or recurrent thrombotic events. 
Methods: Platelet activation units (PAU) were measured using the Ultegra-Rapid Platelet 
Function Assay (Ultegra-RPFA), a simple, point-of-care assay in 201 patients presenting 
to the ED with the primary complaint of chest pain and either known coronary disease or 
multiple cardiovascular risk factors. In hospital MACE (death, MI, and urgent target ves- 
sel revascularization) and discharge diagnoses were recorded. 
Results: Baseline platelet function ranged from 44 to 315 PAU (median 171). In patients 
with PAU below the sample median, corresponding to greater platelet activation, the like- 
lihood of an in-hospital troponln positive Ml was 1.8 times that of patients with lower 
platelet activation (24.7% versus 13.5%, p=O.O4 by chl-square). Six month outcomes 
data continue to be collected. 
Conclusion: In patients presenting to the ED with chest pain, low PAU is associated wth 
higher risk of developing in-hospital myocardial infarction. Low PAU is representative of 
greeter platelet activation and IS rapidly determined by the Ultegra-RPFA. Its association 
with long-term risk, correlation with other established risk factors, and variabikty over 
time are under investigation. 
1124-91 Glycoprotein llb/llla Receptor Antagonism in Patients 
With Acute Coronary Syndromes and Prior Coronary 
Artery Bypass Grafting: Results From PRISM PLUS 
Steohen J. Servoss, Ying Wan, Steven M. Snapinn, Peter M. DiBattiste, Pierre Theroux, 
Ik-Kyung Jang, James L. Januzzi, Jr., Massachusetts General Hospital, Boston, MA, 
Montreal Heart Institute, Montreal, PQ, Canada 
Background: Prior coronary artery bypass grafting (CABG) is a predictor of recurrent 
ischemic events in patients presenting with acute coronary syndromes (ACS). The rela- 
tive efficacy of glycoprotein llbillla platelet receptor antagonists in this patient group 
remains undefined. The aim of this study was to assess the role of tirofiban in patients 
with non-ST elevation ACS and prior CABG. 
Methods: Of 1,570 patients treated with either tirofiban plus heparin (T+H, n=773) or 
heparin alone (H, n=797), 231 (16% and 13% in each treatment group, respectively) had 
prior CABG. Treatment outcomes of patients with and without prior CABG were com- 
pared with respect to the composite endpoint of death, myocardial infarction (MI), or 
refractory ischemie (RI). 
Results: Compared to patients without prior CABG, those patients with prior CABG were 
more likely to have risk factors for a complicated ACS course, including advanced age, 
multivessel coronary artery disease, heart failure, and prior aspirin use (all ~~0.0001). 
The frequency of diabetes among patients with and without prior CABG did not differ sig- 
nificantly. After adjusting for potential confounders, compared to those patients without 
prior CABG, those patients with prior CABG were much more likely to suffer adverse 
ACS outcomes (death, Ml or RI) across all time points examined (p< 0.0001). Among 
patients with prior CABG, reductions I” the composite endpoint were generally similar 
with T+H versus H alone at 48 hours, 7, 30, and 180 days (6.5% vs 14.0%, p=O.O9; 
16.9% vs 29.0%, p=O.O35; 25.0% vs 40.2%, p=O.O15; 37.1% vs 48.6%, p=O.O57). The 
benefit of treatment with T+H among patients without prior CABG was statistically signifi- 
cant at the 7 day composite endpoint only (12.2% vs 16.2%, p=O.O27). Rates of percuta- 
neous coronary intervention were similar between patients with and without prior CABG 
(28.6% vs 32.5%, p=NS), and no difference existed with respect to major bleeding rates 
between the groups (0.9% vs 1 .l%, p=NS). 
Conclusions: Patients with prior CABG represent a population at high risk for ischemic 
complications of ACS. Tirofiban was well tolerated and effective in reducing the consider- 
able risk for ischemic ACS complications in patients wth prior CABG. 
1124-92 Preintervention Restoration of Coronary Flow in 
Patients With ST Elevation Acute Myocardial Infarction 
Is Associated With Better Angiography and Clinical 
Outcomes 
Shlomi Matetzk, Marko Not, Neal Eigler, Bojan Cercek, Heart Institute, Sheba Medical 
Center, Tel Hashomer, Israel. Cedars-Sinai Medical Center, Los Angeles, CA 
Background: In patients undergoing primaly angioplasty (PCI) for ST elevation myocar- 
dial infarction (STEMI) without routine use of stents or Ilb/llla antagonists, pre-interven- 
tion restoration of coronary flow in the infarct related artery (IRA) is associated with 
higher PCI success and subsequently improved outcome. Ratification of these findings in 
patients treated with contemporary strategies of primary PCI may influence pre-interven- 
tional management. 
Methods: The significance of pre-intervention IRA patency was studied in 173 consecu- 
tive patients with STEMI who underwent primary PCI with routine stent deployment and 
administration of Ilb/llla antagonist unless contraindicated. Prior to the intewention, 
patients were treated with chewable asplrin (160-325mg) and heparin (70u/kg as a bolus 
followed by 1000 u/h+ 
Results: Fifty-five patients (31.8%) had TIMI flow 11-111 in the IRA (Group A) and 118 
(68.2%) had TIMI flow O-I (Group B), on initial angiogram. There were no significant dif- 
ferences in the baseline demographic characteristics, distributton of the IRA and extent 
of coronary artery disease between Groups A and 8. Despite equally high usage of llbl 
llla antagonists (72% vs 82.5%, p = 0.88) and stents (94% YS 88%, ~~0.8). Group A ver- 
sus Group B patients had higher PCI success rate (98.3% vs 84.6%. p = 0.02) mainly 
due to a three-fold higher incidence of achieving TIMI flow <III. despite widely dilated epi- 
cardial IRA. Group A versus Group B had a lower incidence of shock or CHF (24% vs 8% 
p=O.Ol l), malignant ventricular arrhythmias (17% YS 2.3%, p=O.l), mortality (5.9% vs 
1.8%, p=O.44) and need for IABP, ventilation and/or temporary pacemaker (24% vs 9% 
p=O.O23). 
Early benefit in survival wthout CHF in Group A patients was sustained throughout long- 
term follow-up (30+10 months), as demonstrated by the Kaplan-Meire analysis (p=O.O5). 
Conclwons: Even in the era of routine use of intra-coronary stent and Ilb/llla antago- 
nists, pre-intervention restoration of coronary flow in the IRA is associated with improved 
primary PCI results. 
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1124-93 Relation of Prothrombotic Platelet Polymorphisms to 
the First Manifestation of Coronary Artery Disease in 
Middle-Aged Males 
Jussi Mikkelssoq Lassi Narhi, Markku Eskola. Elina Ollikainen, Kari Pietila, Kjell Nikus, 
Kari Niemela. Pekka J. Karhunen, University of Tampere. Tampere, Finland, Tampere 
University Hospital, Tampere, Finland 
Background: Sudden death is often the first manifestation of the underlying disease, 
being by far the leading first symptom of CAD in early middle age. 90% of CAD mortality 
in individuals under 55 occurs out-of-hospital and is in most cases due to Ml as the pri- 
mary manifestation of CAD. Family history of premature CAD is a strong indicator of Ml 
risk in early middle age. Platelet GPlb-IX-V receptors are activated after plaque rupture 
and bind to subendothelial collagen via vWF. This is followed by direct binding of platelet 
GPleIlla and GPVI collagen receptors to collagen followed by aggregation of platelets 
due to the activation of GPllb/llla fibrinogen receptors. 
Methods and Results: We performed a primary study on the frequencies of several poly- 
morphisms located in the genes encoding these 4 platelet glycoproteins I” a settmg of 
different primary manifestations of coronary artery disease: 1) men with fatal acute Ml 
(n=40), 2) hospitalised men wth acute MI, of which 84% STE-MI (n=llO) and 3) men 
with stable CAD without the history or evidence of unstable CAD/MI (n=50). The PIAZ 
allele of GPllla polymorphism was more often (32%) carried by men with fatal acute MI 
as opposed to men with stable CAD (21%) (OR 1.8). This was especially evident in men 
under 60 yrs (OR 4.1) (45% vs. 17%). Hospitalised suwivors of STE-MI were more often 
carriers of the PIA allele of GPllla (28%) as well as the C allele of the GPlb Kozak poly 
morphism (32%) compared to men with stable CAD (21% and 18% respectively) 
(respective ORs 1.5 and 2.2). These differences between STE-MI and stable CAD were 
especrally clear in men under 80 yrs (27% vs. 17%, OR 2.0 for GPllla; 36% vs. 20%, OR 
2.4 for Kozak). None of the platelet polymorphisms was more frequent among men with 
fatal as opposed to non-fatal Ml. Conclusions: We conclude that the PIA allele of GPllla 
fibrinogen receptor and Kozak C allele of GPlb vWF receptor are associated with an 
increased risk of unstable first manifestation of coronary disease in early middle age. The 
risk associated with the PIA allele was evident for both fatal and non-fatal MI compared 
to the Kozak C allele which seemed to be associated with an increased likelihood of non- 
fatal Ml only. 
1124-94 Predictors of llblllla Platelet Antagonist Use in an 
Unselected Registry of Acute Coronary Syndrome 
Patients 
James E. Calvin. Jr., Peter Meyers, Anthony Joseph, Allan Jaffe, TRACS Investigators, 
Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL 
Background: llbillla platelet blocking agents are used frequently for the treatment of 
patients with acute coronary syndromes (ACS), often during angiography. We sought to 
determine the frequency of Ilb/llla use and factors associated with its use in the Emer- 
gency Department (ED) and/or hospital prior to coronary intervention. 
Methods: The Registry of Acute Coronary Syndromes (TRACS) is a database com- 
prised of 9 institutions that was established to track the quality of care of ACS. Three 
thousand four hundred and sixty four patients were registered, 1,680 of whom were 
admitted. 
Results: Of the admitted patients, 36% were treated with a Ilb/llla platelet blocker but 
only 15% of these before coronary intervention. Patients treated pre-intervention were 
more likely male (87% vs 55%, p c.001) and were younger (66 vs 71 y, p <. 01) com- 
pared to untreated patients. There were no difference in the frequency of troponin eleva- 
tions between the two groups (36% vs 35%) nor, differences in conventional coronary 
artery disease risk factors. However, patients who were treated early received aspirin 
(53% vs 45%, p=.OOl). beta blockers (31% vs 19% p= .OOl), and coronary intewentions 
(67% vs 13%, p<.OOl) more frequently. Only 4.5% of patients receiving a Ilb/llla platelet 
blocker died compared to 9.1% who did not (pc.003). 
Conclusion: Ilb/llla platelet blockers are used in the ED and hospital prior to intervention 
in a minority of cases even in patients with elevated troponins. However, early Ilb/llla use 
is associated with lower mortality These data suggest the need for re-evaluation of how 
llbillla platelet blockers are utilized. 
